Mansoor Sahar Rostami, Ghasemi-Kasman Maryam, Yavarpour-Bali Hanie
Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.
Neuroscience Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.
Int Rev Immunol. 2022;41(2):57-71. doi: 10.1080/08830185.2020.1826474. Epub 2020 Sep 30.
Despite numerous studies on multiple sclerosis (MS) and understanding many aspects of this disease, researchers still struggle to find proper biomarkers that facilitate diagnosis; prognosis and monitoring of treatment efficacy in MS. MicroRNAs (miRNAs) are considered as endogenous, comparatively stable and small non-coding RNAs involved in various biological and pathological signaling pathways. Interestingly, miRNAs have been emerged as a potential biomarker for monitoring novel therapies in MS patients. In this review, we described the miRNAs alteration in the MS patients as well as their altered expression in patients under common MS therapies.
尽管针对多发性硬化症（MS）进行了大量研究并对该疾病的许多方面有所了解，但研究人员仍在努力寻找有助于MS诊断、预后评估和治疗效果监测的合适生物标志物。微小RNA（miRNA）被认为是参与各种生物和病理信号通路的内源性、相对稳定的小非编码RNA。有趣的是，miRNA已成为监测MS患者新疗法的潜在生物标志物。在本综述中，我们描述了MS患者体内miRNA的变化以及它们在常见MS治疗方案下患者中的表达改变。
